ArticleBMC complementary medicine and therapies2026
Hesperidin attenuates gentamicin-induced testicular toxicity via modulation of the PI3K/AKT signaling pathway.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hesperidin attenuates gentamicin-induced nephrotoxicity: Association with SIRT3 and PAX2 expression, oxidative stress, and tubular injury.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGentamicin is an aminoglycoside antibiotic widely used in the treatment of Gram-negative infections; however, one of its major limitations is testicular toxicity. Oxidative stress is considered to play a central role in gentamicin-induced testicular damage. Hesperidin is a natural flavonoid with potent antioxidant and cytoprotective properties and may exert protective effects on the reproductive system.
methodsThis study investigated the protective effects of hesperidin against gentamicin-induced testicular damage. Histopathological and immunohistochemical evaluations were performed alongside biochemical and hormonal analyses. In addition, sperm concentration, motility, and the rate of abnormal spermatozoa were assessed. To elucidate the underlying molecular mechanisms, the gene expression levels of PD-1, PI3K, and AKT-1 were analyzed.
resultsGentamicin administration was associated with lower Johnsen scores, decreased testosterone levels and sperm motility, increased sperm abnormalities, elevated MDA concentrations, reduced CAT, SOD, GPx, and GSH levels, increased Caspase-3 and 8-OHdG immunoreactivity, and reduced AKT expression. Hesperidin co-administration significantly attenuated many of these alterations, being associated with improved histopathological scores, enhanced antioxidant status, reduced immunoreactivity of oxidative stress- and apoptosis-related markers, improved sperm quality parameters, and increased PI3K and AKT gene expression compared with the gentamicin-treated group.
conclusionThese findings indicate that hesperidin possesses a protective potential against gentamicin-induced testicular damage, likely mediated through its antioxidant and anti-apoptotic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.